Efficacy and safety of calcipotriene/betamethasone dipropionate foam in psoriasis people

Summaries 3 min 306

Font Size

Created On: 08/04/2022

A prospective, open-label, single-arm study aimed to investigate safety and efficacy of calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for psoriasis management.

See All

Key take away

In adults patients having moderate-to-severe chronic plaque psoriasis, adjunctive treatment with calcipotriene/betamethasone dipropionate foam led to sustained improvements in disease control.

Background

A prospective, open-label, single-arm study aimed to investigate safety and efficacy of calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for psoriasis management.

Method

In total, 25 patients (mean age: 50 years) with chronic plaque psoriasis who had localized residual plaques and exhibited suboptimal response after ≥24 weeks of treatment with ixekizumab monotherapy were enrolled. All the subjects continued ixekizumab biologic therapy and were given Cal/BD foam once daily for about four weeks. This was followed by every other day for weeks eight to twelve.

Treat-to-target body surface area (BSA) ≤1% at week 4 was the major outcome. Other outcomes included patient-reported Dermatology Life Quality Index (DLQI), Physician’s Global Assessment (PGA) score and PGA×BSA. Safety assessments included an investigation of local skin reactions and adverse events.

Result

Notably, 56% of people attained the treat-to-target goal of ≤1% BSA following 4 weeks of daily Cal/BD foam. After 4 weeks of addition of Cal/BD foam, a reduction in the score of composite PGA×BSA, mean PGA, and mean % BSA involvement was witnessed. After decreasing the dosing frequency of Cal/BD, improvements in the disease severity outcomes were found to be maintained. Cal/BD was well-tolerated and safe. No major side effects were noted.

Conclusion

In real-world clinical practice, Cal/BD foam was safe, exhibited good tolerability and was linked with remarkable improvements in disease control in psoriasis people who had residual plaques after ≥24 weeks of ixekizumab treatment.